Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

NCT00865605 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Halobetasol Propionate 0.05% Ointment, single exposure
DRUG: Ultravate® 0.05% ointment, single exposure

Sponsor

Actavis Inc.